Sponsored information from

Primary care Action Interactive Cases

Return to homepage 

David, 59

David is a 59-year-old male who works as a security guard.

He visits you to for a regular check-up appointment.

Patient history and current medications

  • Type 2 diabetes (T2D) diagnosis 7 years ago
  • Metformin (7 years), sulphonylurea (5 years), SGLT-2i (2 years)
  • Dyslipidaemia, 3 years (statin)
  • Hypertension, 3 years (ACE inhibitor)
  • Non-smoker and minimal alcohol intake
  • Previous assessment:
    • HbA1c 6.8% (51 mmol/mol)
    • BP 121/79 mmHg
    • LDL cholesterol 1.4 mmol/L
    • ALT 45 U/L and AST 35 U/L
    • BMI 29 kg/m2

Current clinical measurements

  • BMI 30 kg/m2
  • HbA1c 6.9% (52 mmol/mol)
  • BP 125/77 mmHg
  • Total cholesterol 3.7 mmol/L
  • LDL cholesterol 1.5 mmol/L (58 mg/dL)
  • ALT 47 U/L and AST 69 U/L
  • Additional information:
  • eGFR 84 mL/min/1.73 m2

ACE: angiotensin-converting enzyme; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BP: blood pressure; eGFR: estimated glomerular filtration rate; FIB-4: Fibrosis-4 index; LDL: low-density lipoprotein; SGLT-2i: sodium-glucose cotransporter-2 inhibitor

Hide medical notes 
Clinical data 

This is a fictional case study. The model is not a real patient and the situation shown does not reflect the model's experience.

References
  1. Vieira Barbosa J, Milligan S et al. Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD. Hepatol Commun 2022;6(4):765-779
  2. Loomba R, Adams L A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 2019;70(6):1885-1888
  3. Sterling R K, Lissen E et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317-1325
  4. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ 2014;349:g4596
  5. Rui F, Yang H et al. Renaming NAFLD to MAFLD: advantages and potential changes in diagnosis, pathophysiology, treatment, and management. Infectious Microbes & Diseases 2022;4(2)
  6. Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9
  7. UpToDate. Patient education: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) (Beyond the Basics). Available at: uptodate.com. Accessed March 2023
  8. Sanyal D, Mukherjee P et al. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab 2015;19(5):597-601
  9. Dyson J K, Anstee Q M, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5(3):211-218
  10. Cusi K, Isaacs S et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored bythe American Association for the Study of Liver Diseases (AASLD). Endocrine Practice 2022;28(5):528-562
  11. Rinella M E, Neuschwander-Tetri B A et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023 (Epub ahead of print)
  12. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388-1402
  13. Srivastava A, Gailer R et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol 2019;71(2):371-378
  14. NAFLD fibrosis score online calculator. Available at: omnicalculator.com. Accessed March 2023
  15. Younossi Z M, Felix S et al. Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease. JAMA Netw Open 2021;4(9):e2123923
  16. Xiao H, Shi M et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis. PLoS One 2017;12(11):e0186660
  17. Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol 2019;25(40):6053-6062
  18. National Institute for Health and Care Excellence (NICE). NICE clinical guideline 49. Non-alcoholic fatty liver disease (NAFLD): assessment and management, July 2016. Available at: nice.org.uk. Accessed March 2023
  19. Tapper E B, Challies T et al. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2016;111(5):677-684
  20. Hallsworth K, Adams L A. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep 2019;1(6):468-479